MTOR and nonpapillary renal cell carcinoma: Metastatic ccRCC (mRCC) does not respond to cytotoxic chemotherapy, and systemic therapy primarily targets the VEGF or mTOR pathway or more recently includes target immune cells through the use of immune checkpoint inhibitors [2–4].